In a randomized, season-long study of 26 NCAA Division I football players, active intranasal and transcranial photobiomodulation with a Vielight Neuro Gamma device preserved or improved diffusion MRI markers linked to neuroinflammation and axonal stress compared with sham. Over a 16-week competitive season with equivalent contact exposure, the sham group showed increases in measures such as restricted diffusion imaging and quantitative anisotropy, while the active group maintained relative stability with region-specific reductions, indicating a potential mitigation of sub-concussive brain changes.
The core development is publication of these data in the Journal of Neurotrauma, marking one of the first intervention trials conducted under real-world, in-season conditions for repetitive head impacts. Athletes self-administered 20-minute sessions three times weekly under supervision in the training facility, using a medical-grade photobiomodulation system designed to deliver pulsed near-infrared light to cortical networks. The signal is biomarker-based rather than clinical, but the institutional response is notable: one program has already moved to incorporate the device into standard equipment for athletes, underscoring operational feasibility and early adoption momentum.
Strategically, this is a bid to translate photobiomodulation from wellness-adjacent territory into regulated, evidence-backed use for neurological protection. The choice to anchor efficacy to advanced imaging biomarkers and to run a pragmatic, in-season protocol avoids the confounders of reduced contact exposure and tackles the adherence problem head-on with supervised dosing. It also positions the device as complementary to equipment and protocol changes rather than a substitute. The tension is clear: the dataset is small, limited to surrogate endpoints, and not powered for functional outcomes. Any prevention or protection claims will face regulatory scrutiny, likely requiring a stepwise path that includes biomarker qualification and, ultimately, clinical endpoints relevant to cognition, symptoms, or long-term neurodegeneration.
For sponsors and CROs, the study offers a template for prevention trials in head-impact cohorts: randomized designs tied to a competitive season, centralized diffusion MRI acquisition and analysis, and integration with head-impact exposure metrics. Sites embedded in sports medicine and neurology programs may see new demand for longitudinal imaging infrastructure, adherence monitoring, and training-room workflows that can accommodate device-based interventions without disrupting athletics operations. Vendors in imaging analytics and digital adherence tools will find openings to support standardized pipelines across multicenter trials. Regulators are likely to probe the linkage between diffusion MRI changes and clinically meaningful benefit, elevating the importance of convergent endpoints such as neurocognitive batteries and plasma biomarkers like NfL, GFAP, and tau. Athletic departments and payers will weigh device cost and logistics against incremental protection layered onto helmets, practice limits, and return-to-play protocols.
What comes next will determine whether this moves beyond an intriguing signal. Multicenter, adequately powered trials across multiple seasons, with prespecified imaging and fluid biomarkers and blinded, credible shams, will be essential. Sponsors will need to demonstrate durability, dose-response, and feasibility of home-use regimens without supervised administration. Expansion to other collision sports and adolescent populations brings both opportunity and added regulatory complexity. Key risks include masking challenges inherent to light-based devices, small-sample bias, and heterogeneity in imaging acquisition. Watch for replication in independent cohorts, alignment with FDA’s biomarker and device qualification frameworks, and inclusion of patient-relevant outcomes. If those pieces align, photobiomodulation could emerge as a scalable adjunct to current safety measures, but the burden of proof now shifts to larger, operationally rigorous studies that can carry a prevention claim through review.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
